IPF Drug Esbriet Now Publicly Funded in Canadian Province

October 15, 2014 8:20 PM

15 0

New Brunswick, Canada residents currently in the fight against a rare and mysterious disease, idiopathic pulmonary fibrosis (IPF), have received new hope after it was announced that the provincial government has added Esbriet (pirfenidone) to the list of treatments publicly funded under the New Brunswick Prescription Drug Program (NBPDP). This is a significant development in the country’s movement against this life-threatening and debilitating disease, as Esbriet is currently the only approved drug for IPF available in Canada. The government’s decision to fund Esbriet comes after 2 long years of petitioning and rallying for public access, and complies with an agreement with the Pan-Canadian Pharmaceutical Alliance (PCPA). As of October 3, 2014, New Brunswick is officially the 2nd Canadian province after Ontario to fund this treatment for IPF patients that meet certain criteria.

The advocacy for access to Esbriet in New Brunswick began in 2012 when the drug was approved by Health Canada, but was recommended by the Common Drug Review (CDR) to be available for public funding only in select Canadian provinces. This left many IPF patients without access to a reliable treatment ...

Read more

To category page